His name is Clay Siegall and he is the founder and also the CEO of his company Seattle Genetics, a biotech firm which specializes in targeted therapy medication development for things that have not yet seen progress towards cures.
Dr. Siegall obtained a Bachelors degree of zoology at the University of Maryland. He also holds despite Ph.D. of genetics from George Washington University.
Since Clay Siegall started Seattle Genetics he’s led it towards becoming one of the leading companies in the field of targeted therapies and they are the very first antibody-drug company to be FDA and they now hold numerous approved drugs. Seattle has also made a huge portfolio including 20 medicines. They have vital connections with drugmakers such as Pfizer, Genentech, Bayer, and many others.
Under Clay’s control, the company Seattle Genetics changed a small firm and a little research team to becoming a formidable player in the field of cancer research. Dr. Siegall has lofty goals for Seattle Genetics future. With an expansive list of medicines in the development process and a huge list of uses for their current list of drugs, Seattle Genetics is prepped to go into new levels of medicine development.
In Dr. Siegalls view, common styles of cancer treatment such as chemotherapy is going the way of the past. Clay thinks targeted therapies are more cost effective and more efficient, and pending further development, the industries prior methods are going to be supplanted by targeted therapy which is more effective.
Dr. Siegalls passion for medicine started with his longtime admiration of the medical field, and how technologies and innovations could be potentially used in the future to treat illnesses. Dr. Clay Seigall got interested in cancer treatment while he took zoology at Maryland University and one of the members in his family got sick. The way the doctors treated it was way too severe and they became seriously anemic and the chemotherapy almost was fatal.
Clay Siegall has raised over $600 million in private and public financing, including an initial IPO in the year of 2001. Before Clay co-founded Seattle Genetics, he was working for Bristol-Myers Pharmaceutical Institute.